Product Press Release
HERCULES, CA –September 28, 2015 – Bio-Rad Laboratories, Inc.(NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced the launch of human recombinant protein antigens, which expand the company’s critical raw material offering.
The recombinant proteins provide Bio-Rad’s diagnostics partners with the value and reliability required of their critical assay components including markers for use in Down’s syndrome, ovarian cancer, infertility and myocardial infarction testing.
“Bio-Rad is proud to offer expanding support and commitment to our valued diagnostic customers,” said Conrad Maurais, Product Manager, Bio-Rad. “The biomarkers are used in numerous diagnostic tests and aid in scientific research.”
The New Antigens Include:
- Inhibin A – included in prenatal pregnancy screens as a marker for Down’s syndrome and has relevancy in ovarian cancer and male infertility.
- Creatine Kinase MB Isoenzyme (CK-MB) enzyme – is used as a follow-up test for the biochemical diagnosis of myocardial infarction.
- Follicle-stimulating hormone – synthesized and secreted in the anterior pituitary, regulating the development growth, pubertal maturation and reproductive processes.
With over 25 years of experience providing critical raw materials, Bio-Rad is a leading provider of tumor marker antigens. For more information, please call 207-615-0571 or visit www.bio-rad.com/CRM
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,600 people worldwide and had revenues exceeding $2.1 billion in 2014. For more information, please visit www.bio rad.com.
Press contact:
Bio-Rad Laboratories, Inc.
Conrad Maurais, Product Manager
207-615-0571
Email: conrad_maurais@bio-rad.com